Shuai Li

Shuai Li

Auto-generated profile, based on publicly available information

Shuai Li

Innovation Center of Cardiometabolic Diseases, Guangdong Medical University

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
RRRensen Ran
Rensen Ran
LLLanxin Li
Lanxin Li
PCPeng Chen
Peng Chen
SLShuai Li
Shuai Li
PWPeng Wang
Peng Wang
WLWeizheng Liang
Weizheng Liang
Targeting exogenous gene integrations in animals often exhibits low efficiency, limiting the development of gene knock-in models. Theoretically, by screening founder generation individuals based on the cell phenotypes resulting from gene knock-ins and leveraging the high fecundity of animals, heritable descendants with targeted knock-ins can be efficiently generated. Therefore, we utilized the high fecundity of Xenopus tropicalis and easily observable pigment phenotypes to construct a BRAF V600E -targeted mitf locus knock-in model. Results indicated that this approach enabled efficient generation of BRAF V600E knock-in X. tropicalis and produced a versatile frog model. The BRAF V600E knock-in induced the transdifferentiation of RPE cells into retinal cells, resulting in a symmetric retinal structure in the eyes of these frogs. The transformation of RPE cells ultimately leads to these frogs becoming eyeless frogs, which serve as a tool for retinal regeneration research. Additionally, in eyeless frogs the BRAF V600E knock-in led to the abnormal proliferation of both melanocytes and xanthophores into melanocytic and xanthocytic nevi respectively. Consequently, eyeless frogs provide a model for studying abnormal pigment cell proliferation, offering a platform for investigating pigment cell nevus formation. Furthermore, the cdkn2b -knockout eyeless frogs serve as a valuable xanthophoroma model for tumor biology research. Overall, the BRAF V600E -targeted knock-in X. tropicalis not only represents a strategy for constructing gene knock-in animal models but also serves as a versatile tool for research in retinal regeneration and tumor biology.

30 June 2025 in Pharmacognosy Magazine
Verified
Journal Article
Open access
XCXiong-Bin Cao
Xiong-Bin Cao
JCJun Cai
Jun Cai
BLBo Liu
Bo Liu
XWXiang-Feng Wu
Xiang-Feng Wu
ZWZhi-Qiang Wei
Zhi-Qiang Wei
LGLi Gong
Li Gong
Background and Objectives: Parkinson’s disease (PD) is a common age-related neurodegenerative disorder. Mitochondrial dysfunction is considered an important initiating factor for the lack of dopaminergic (DA) neurons. Therefore, identifying drugs that effectively protect DA neurons from mitochondrial damage represents a promising therapeutic strategy. Materials and Methods: In this study, an anti-atherosclerosis (AS) drug, Ziziphora clinopodioides flavonoids (ZCF), was shown to inhibit 1-methyl-4-phenylpyridinium (MPP + )-induced DA neuron damage in vitro and in vivo and this was verified by a variety of experimental methods. Cell viability assays, cell fluorescence staining, Western blot experiments, flow cytometry analysis, and quantitative real-time polymerase chain reaction (qPCR) experiments were conducted to assess the protective effect and mechanism of ZCF on SH-SY5Y cells. Additionally, behavioral tests and immunohistochemistry (IHC) were performed to validate the protective effect of ZCF in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD animal model. Results: ZCF significantly ameliorated MPP + -induced cell viability loss and elevated lactate dehydrogenase (LDH) in SH-SY5Y cells. Moreover, ZCF treatment improved mitochondrial morphological abnormalities, reduced adenosine triphosphate (ATP) content, attenuated mitochondrial membrane potential loss, cell apoptosis, mitoROS levels, and increased the level of tyrosine hydroxylase (TH). Further results indicate that ZCF treatment significantly stimulated the phosphorylation of AMP-activated protein kinase (AMPK) and its downstream target miR-181b. Additionally, the blockage of the level of AMPK with Compound C or knocking down the expression of miR-181b significantly attenuated the protective effect of ZCF. These results indicate that the AMPK/miR-181b axis plays a vital role in the protective effect of ZCF. Moreover, ZCF treatment alleviated MPTP-induced motor dysfunction and loss of TH-positive neurons in the PD mice model. Conclusion: In brief, our findings suggest that ZCF may have potential applications for the treatment and prevention of PD.